Inhaled AAT (KMA-001)
Alpha-1 Antitrypsin Deficiency (AATD) with emphysema
Key Facts
About Kamada
Kamada is a profitable, vertically integrated biopharmaceutical company with a mission to provide high-quality therapeutics for rare and serious conditions. The company has achieved record financial performance, driven by its commercial plasma-derived products, a robust development pipeline led by an inhaled Alpha-1 Antitrypsin candidate, and a strategic CDMO business. Its strategy is built on a three-pillar model: commercial execution, innovative R&D, and leveraging its industry-leading manufacturing capabilities for organic and partnership-driven growth.
View full company profile